NIAID Strategic Plan for COVID-19 Research, FY2020-FY2024

NIAID Strategic Plan for COVID-19 Research, FY2020-FY2024 (National Institute of Allergy and Infectious Disease, April 22, 2020, 10p)

NIAID, part of the US National Institutes of Health, “is committed to safeguarding the health of Americans and people around the world by accelerating research efforts to prevent, diagnose, and treat COVID-19.” This strategic plan, structured around four research priorities, “builds on current trans-NIAID efforts to better understand SARS-CoV-2 pathogenesis, transmission, and mechanisms of protective immunity.”

  1. Improve fundamental knowledge about the virus;
  2. Support development of diagnostics and seriologic assays;
  3. Characterize and test therapeutics;
  4. Develop safe and effective vaccines, and advance promising candidates through clinical trials.

Note: NIAID is directed by Dr. Anthony S. Fauci, widely-known to Americans as the leading expert in this field. Also, see McKinsey & Company “COVID-19 Briefing Materials”, noting >80 vaccine candidates and 130 therapeutic candidates being considered as of April 13.  NIAID is directed by Dr. Anthony S. Fauci, widely-known to Americans as the leading expert in this field.

Scroll Up
Wordpress Social Share Plugin powered by Ultimatelysocial